MoonLake Immunotherapeutics (MLTX) Cash from Investing Activities (2021 - 2026)

MoonLake Immunotherapeutics' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at $98000.0 for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 99.83% year-over-year to $98000.0; the TTM figure through Mar 2026 stood at $146.8 million (up 221.82% YoY), while the FY2025 annual figure was $203.0 million, up 198.73% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $98000.0, up from -$29.9 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $116.9 million in Q4 2023, with the low at -$174.4 million in Q3 2023.
• The 5-year median for Cash from Investing Activities is $98000.0 (2026), against an average of -$3.5 million.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities plunged 362386.24% in 2022, then jumped 633802550.0% in 2023.
• MoonLake Immunotherapeutics' Cash from Investing Activities stood at $9.9 million in 2022, then soared by 1080.3% to $116.9 million in 2023, then sank by 226.07% to -$147.3 million in 2024, then soared by 79.7% to -$29.9 million in 2025, then soared by 100.33% to $98000.0 in 2026.
• Business Quant data shows MLTX's Cash from Investing Activities at $98000.0 in Q1 2026, -$29.9 million in Q4 2025, and $88.4 million in Q3 2025.